The characteristics of different types of epidermal growth factor receptor (EGFR) gene mutations in non-small-cell lung cancer (NSCLC) are not extensively studied. The distribution of EGFR mutations is known, with the most frequent in exon 19 (deletions) or exon 21 (point mutations). Aberrations in exon 18 or 20 are infrequently found. Point mutations in exon 20 confer resistance against tyrosine kinase inhibitors (TKIs), whereas the effect of the rare exon 20 insertions is, to a lesser extent, known. We present clinicopathological characteristics of patients with EGFR mutations in the four exons, with emphasis on exon 20 positive patients.
M
etastatic non-small-cell lung cancer (NSCLC) is invariably a deadly disease. Nevertheless, the aggressiveness is variable, with differences in both the natural course and in treatment effects. The presence of mutations in the kinase domain of epidermal growth factor receptor (EGFR) gene has been regarded as both a positive prognostic and predictive marker, and most EGFR mutation-positive patients respond well to tyrosine kinase inhibitors (TKIs) such as gefitinib or erlotinib.
1,2 However, it is now increasingly clear that not all EGFR mutations confer sensitivity to TKIs, and, especially, point mutations in exon 20 are regarded as markers of resistance to this kind of therapy. [3] [4] [5] [6] Not much is known about the response in the presence of other lowfrequent mutations within the kinase domain of EGFR. Here we report the clinicopathological characteristics of EGFR-mutated patients and the selective treatment responses of exon 20 mutations in an unselected material of mutation-positive patients.
PATIENTS AND METHODS
In Norway, all patients diagnosed with NSCLC since May 2010 have been recommended for testing for the presence of EGFR mutations. Approximately 900 tests are now performed every year at our institution, Oslo University Hospital, Oslo, Norway. Mutation analysis of EGFR exons 18 to 21 is performed using the TheraScreen EGFR mutation kit (DxS, Manchester, United Kingdom). The assay is designed to detect 28 specific mutations in the EGFR gene by real-time polymerase chain reaction. It enables the detection of 19 distinguished deletions in exon 19, L858R, L861Q, G719X, S768I, and three insertions in exon 20. Assays were carried out according to the manufacturer's protocol and by using the Roche LightCycler 480 (Roche Diagnostics, Mannheim, Germany) real-time polymerase chain reaction system. Data analyses were performed using the LightCycler Adapt software (LightCycler 480 Software, v1.5). Some samples were analyzed using denaturing high-performance liquid chromatography followed by sequencing as previously described. 7 We retrospectively reviewed patients who tested positive for EGFR mutations between May 2010 and February 2012 at our institution.
RESULTS
A total of 119 patients testing positive for EGFR mutations were identified; 74 women (62.2%) and 45 men (37.8%). The median age was 66.0 years, and 1-year overall survival after time of tissue sampling was 84.2% whereas median overall survival from sampling was 38.7 months. See Table 1 for differences in frequency, sex, and age among the four main mutation types. Four patients had more than one mutation: two had G719X, S768I, one had G719X, L861Q, and one had del19, T790M. This latter patient was sampled upon resistance after 11 months of TKI therapy (no pretreatment sample is available); all the other exon 20 positive patients were sampled before starting systemic therapy. All exon 20 positive patients were whites.
Seven of the 11 exon 20 positive patients have been treated with TKIs, all of whom have been response evaluated. The del19-, T790M-positive patient, sampled at progression, had partial response and was treated with TKI for 11 months until progression. One patient with double mutation (S768I, G719X) has now been on treatment for 14 months with a partial response. The other five patients have had progressive disease at evaluation after 1 to 3 months of treatment. Details of the 11 patients are listed in Table 2 .
DISCUSSION
We find a distribution of the main mutations in the EGFR gene comparable with that in other findings, 8 with approximately 85% of aberrations found in exons 19 and 21. In our material, 11 of 123 EGFR-mutations (8.9%) were found in exon 20, and most of these were insertions. Interestingly, in three of the four patients with double mutations, one of the mutations was found in exon 20. The finding that mutations in the EGFR gene predict effect of tyrosin kinase inhibitors has led to a paradigm shift in lung cancer care. In Norway, all new cases of NSCLC are tested for mutations in exon 18 to 21. Mutation-positive advanced cases are offered TKI treatment in first or second line. However, it is increasingly clear that not all mutations confer sensitivity to TKIs. As shown, of the six responseevaluated patients with mutations in exon 20 (excluding the one with T790M mutation) only the one with a concurrent mutation in exon 18 has been treated beyond first evaluation. Even though mutations in exon 20 are most uncommon-only 122 cases were found in a recent review 4 -the awareness that these might confer sensitivities to firstgeneration TKIs comparable with wild-type tumors should be emphasized. The exact mechanism of the nonsensitivity is not clarified, and the clinical impact has not been systematically investigated in any study. 4 Interestingly, in this exon 20 positive group only three of 10 patients with known smoking status were never-smokers, compared with eight of 18 patients in an unselected Norwegian EGFRpositive cohort. 7 We have found clinicopathological differences between the main EGFR-mutation types in NSCLC. Even though we report a limited number of exon 20 positive tumors, this adds to a relatively scarce literature on the insensitivity of this mutation type toward erlotinib or gefitinib and underscores that patients harboring this mutation type should be considered for conventional chemotherapy and not first-generation TKIs. Of note, the novel second-or third-generation Characteristics of 11 patients with mutations in exon 20 of EGFR. a This patient was sampled for EGFR-mutation analysis at progression after 11 months of erlotinib treatment. IDs 5, 10, and 11 have been partially reported previously (as T107, T94, and T104, respectively in 7 ). AC, adenocarcinoma; BAC, bronchioloalveolar carcinoma; SCC, squamous cell carcinoma; Ins, insertion in exon 20 (detailed or not specified); F, female; M, male; N/A, not applicable; PD, progressive disease; PR, partial response.
